Exeliom is a clinical-stage biopharmaceutical company tackling the use of commensal bacteria as drugs.
Exeliom has raised $8.7M in total funding. The most recent round was Series A. The last funding was announced in June 2023.
Exeliom's investors include Bpifrance, European Innovation Council, UI Investissement, CE-Ventures, Auriga Partners.
Exeliom is headquartered in Dijon, France.
Exeliom is a clinical-stage biopharmaceutical company tackling the use of commensal bacteria as drugs.
Exeliom is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Exeliom — Funding & Investors." VCBacked, June 30, 2023, https://www.vcbacked.co/company/exeliom. Accessed July 20, 2026.
VCBacked. (2023). Exeliom — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/exeliom
{{cite web |title=Exeliom — Funding & Investors |url=https://www.vcbacked.co/company/exeliom |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated